- Supported exchanges /
- F /
- 2TK.F
ELEDON PHARMACEUT.DL-001 (2TK F) stock market data APIs
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
ELEDON PHARMACEUT.DL-001 Financial Data Overview
| 3.04 | |
| 3.04 | |
| - | |
| 3.04 | |
| 3.04 | |
| 1-3.2 | |
| 132 M | |
| 7.2381 | |
| 41 383 K | |
| 0 | |
| -0.5 | |
| 0.883 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
ELEDON PHARMACEUT.DL-001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA 0
- Earnings Per Share 0.42
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get ELEDON PHARMACEUT.DL-001 Earnings via APIs
- Latest Release 2021-06-30
- EPS/Forecast -0.57
Get ELEDON PHARMACEUT.DL-001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
